RMC-5552
- Generic Name
- RMC-5552
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Nicholas Butowski
- Target Recruit Count
- 48
- Registration Number
- NCT05557292
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04774952
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸UC Irvine - Chao Family Comprehensive Cancer Center, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath